Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Featured trial
FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

  • 270 views
  • 25 Mar, 2021
  • 1 location
Featured trial
ODYSSEY OUTCOME STUDY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

ODYSSEY OUTCOME STUDY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

  • 100 views
  • 25 Mar, 2021
  • 1 location
Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease

cholesterol absorption inhibitors ezetimibe and PCSK9 inhibitor, large-scale clinical studies have been conducted to lower LDL cholesterol using these drugs. In this study, as in the statin study

cardiovascular disease
ezetimibe
LDL Cholesterol
hmg-coa reductase inhibitors
rosuvastatin
  • 0 views
  • 12 Dec, 2021
  • 2 locations
PCSK9 Inhibitor Treatment for Patients With SPG5

SPG5 patients, indicating that elevated levels of oxysterols might be key pathogenic factors in SPG5. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) have

  • 9 views
  • 16 Feb, 2022
  • 1 location
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (PERFECT-AMI)

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary

  • 0 views
  • 06 Jun, 2022
  • 2 locations
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction: a Muti-center, Open-label, Randomized Controlled Trial

This is a multi-center, prospective, randomized, controlled study. The patients with STEMI who were to undergo PPCI were divided into PCSK9 inhibitor group (n=80) and conventional treatment

  • 0 views
  • 23 Sep, 2022
  • 2 locations
Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography (MICROPROTECT)

Proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (anti-PCSK9) significantly reduce the serum LDL-C level, leading to a regression of the coronary epicardial plaque

  • 0 views
  • 06 Jun, 2022
  • 1 location
A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study in Chinese patients with

  • 17 views
  • 29 Apr, 2022
  • 1 location
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients (ACAV)

, nicotinic acid or ezetimibe is not recommended in post-transplant scenario. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) increase availability has emerged as a novel drug tool for LDL

  • 1 views
  • 10 May, 2022
  • 1 location
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome (sICASBLM)

sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C>1.8mmol/L) without endovascular therapy.

  • 0 views
  • 15 Jun, 2022
  • 1 location